Original Research

The association between alcohol consumption and colorectal carcinogenesis is partially mediated by the gut microbiome

Ane Sørlie Kværner^a, Einar Birkeland^b, Ekaterina Avershina^{d,e}, Edoardo Botteri^{a,f}, Cecilie Bucher-Johannessen^{c,d,f}, Markus Dines Knudsen^{g,h}, Anette Hjartåker^g, Christian M. Page^{i,j}, Johannes R. Hov^{k,l,m,n}, Mingyang Song^{h,o,p}, Kristin Ranheim Randel^a, Geir Hoff^{a,q}, Trine B. Rounge^{e,f} and Paula Berstad^a

Author Affiliations

^aSection of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway

^bSection for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway

^cCentre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway

^dDepartment of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway

^eDepartment of Pharmacy, University of Oslo, Oslo, Norway

¹Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway

^gDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

^hDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

ⁱCentre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway

^jDepartment of Physical Health and Ageing, Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway

^kNorwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway

¹Research Institute of Internal Medicine, Division of Surgery and Specialized Medicine, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway

^mFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

ⁿSection of Gastroenterology, Department of Transplantation Medicine, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway

^oDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

^pClinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

^qDepartment of Research, Telemark Hospital, Skien, Norway

Authors' last names

Kværner

Birkeland

Avershina

Botteri

Bucher-Johannessen

Knudsen

Hjartåker

Page

Hov

Song

Randel

Hoff

Rounge

Berstad

Corresponding Authors

Ane Sørlie Kværner

Tel: +47 22 92 89 60

Mailing address: Cancer Registry of Norway, Norwegian Institute of Public Health, Postboks

5313 Majorstuen, 0304 Oslo, Norway

E-mail address: ane.sorlie.kvaerner@kreftregisteret.no

ORCID identifier: 0000-0001-6247-7304

Paula Berstad

Tel: +47 932 932 35

Mailing address: Cancer Registry of Norway, Norwegian Institute of Public Health, Postboks

5313 Majorstuen, 0304 Oslo, Norway

E-mail address: paula.berstad@kreftregisteret.no

ORCID identifier: 0000-0002-9025-4455

Sources of Support

This project would not have been possible without funding from the Norwegian Cancer Society

(grant nos. 190179 and 198048), the Norwegian Cancer Society's umbrella organization for

cancer research ("Kreftforeningens paraplystiftelse for kreftforskning"), the Research Council of

Norway (grant no. 280667) and the South-Eastern Norway Regional Health Authority (grant nos.

2022067 and 2020056). The BCSN trial study was funded by the Norwegian Parliament

(Norwegian national budget from 2011). The bowel preparation used for colonoscopy was

provided free of charge by Ferring Pharmaceuticals. The funders of the study had no role in

study design, data collection, data analysis, data interpretation, or writing of the report.

Short running head: Alcohol, gut bacteria and colorectal cancer

Abbreviations

ACME: Average causal mediation effect

ADE: Average direct effect

ADH: Alcohol dehydrogenase

AICR: American Institute for Cancer Research

ALDH: Acetaldehyde dehydrogenase

BCSN: Bowel Cancer Screening in Norway

BMI: Body mass index

CRC: Colorectal cancer

CUP: Continuous Update Project

CYP2E1: Cytochrome P450 2E1 pathway

E: Exposure

E%: Energy percentage

FFQ: Food frequency questionnaire

FIT: Fecal immunochemical test

KBS: Kostberegningssystem

MaAsLin: Microbiome multivariable associations with linear models

M: Mediator

O: Outcome

PCoA: Principal coordinate analysis

PERMANOVA: Permutational multivariate analysis of variance

Q: Quartile

TE: Total effect

TSS: Total sum scaling

WCRF: World Cancer Research Fund

Trial Registration: The BCSN is registered at clinicaltrials.gov (National clinical trial (NCT) no. 01538550).

Abstract

1

21

2 **Background:** Alcohol consumption is one of the major risk factors of colorectal cancer (CRC). 3 However, the mechanisms underlying this relationship are not fully understood, particularly the 4 potential role of gut microbes. 5 **Objective:** To study associations of alcohol intake with the gut microbiome and colorectal 6 lesions among CRC screening participants. Of particular interest was the potential role of gut 7 microbes in mediating the association between alcohol intake and colorectal lesions. 8 Methods: Participants included fecal immunochemical test-positive women and men enrolled in 9 the CRCbiome study, aged 55-77 years at inclusion. Intake of alcohol was assessed using a 10 validated, semi-quantitative food frequency questionnaire. Integrating with shotgun metagenome 11 based taxonomic and functional profiles, we studied associations with screen-detected colorectal 12 lesions. The potential role of alcohol-associated gut microbes in mediating the association between alcohol intake and colorectal lesions was examined using causal mediation analysis. 13 14 **Results:** Of 1,468 participants with dietary data, 414 were diagnosed with advanced lesions 15 (advanced adenoma, advanced serrated lesions or CRC). Alcohol intake was positively 16 associated with advanced lesions in a dose-dependent manner ($p_{trend} = 0.008$), with odds ratio of 17 1.09 (95% confidence interval, 1.00, 1.19) per 10 g/day increase. Compared to non-consumers, those consuming alcohol were characterized by a distinct microbial profile, manifested as 18 19 modest, but consistent, shifts in α - and β -diversity, and differentially abundant bacteria (Log2) 20 fold change (Log2FC) >0: B. finegoldii and L. asaccharolyticus; Log2FC <0: S. mutans, B.

dentinum, C. symbiosum and E. boltae). A causal mediation analysis showed that 12% of the

22 association between alcohol intake and advanced lesions was mediated by alcohol-associated gut

23 bacteria.

25

27

24 **Conclusions:** Alcohol consumption was associated with a distinct microbial profile, which partly

explained the association between alcohol intake and advanced colorectal lesions.

26 Keywords: Colorectal cancer, advanced colorectal lesions, colorectal carcinogenesis, bowel

cancer screening, FIT, alcohol, food frequency questionnaire, gut microbiome, metagenome

sequencing, α -diversity, β -diversity, differential abundance, mediation

Introduction

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Alcohol increases the risk of cancer at multiple sites, in particular those of the gastrointestinal system¹⁻³. According to recent global estimates, approximately 1 in 20 cancers in 2020 could be attributed to alcohol consumption⁴. Considering the rise in adult per capita consumption seen worldwide, especially in developing countries, these numbers are likely to increase in the years to come⁵. The changing patterns of alcohol consumption among women represent a particular cause of concern⁵. Alcohol (ethanol) is efficiently absorbed by diffusion in the upper gastrointestinal tract, mainly in the stomach and small intestine, before entering the liver via the portal vein⁶. The predominant pathway for alcohol metabolism involves the enzymes alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), converting ethanol to acetaldehyde and acetate, respectively⁶. Alcohol can also be metabolized to acetaldehyde through the cytochrome P450 2E1 (CYP2E1) pathway⁷. Although the liver is the primary site for alcohol metabolism, some alcohol is also catabolized in the gastrointestinal tract, either by mucosal cells lining the gut or bacteria expressing enzymes involved in alcohol metabolism⁷. Alcohol may promote cancer either directly or indirectly through its metabolites (acetaldehyde and acetate) and/or enzymes involved in alcohol metabolism⁷. Their potential carcinogenic effects are multiple, encompassing genomic, biochemical, inflammatory and immunemodulatory mechanisms, among others⁷. More recently, the gut microbiome has emerged as a plausible pathway through which alcohol may promote cancer⁸. However, it remains unclear whether and how alcohol contributes to carcinogenesis through this microbial pathway.

To gain deeper insight into the potential role of gut bacteria in alcohol-associated carcinogenesis, colorectal cancer (CRC) represents a particularly relevant malignancy. Not only are incidence rates highly connected to alcohol consumption (with approximately one in ten new cancer cases attributable to alcohol consumption⁴), but substantial data also support gut microbes as key players in the development of the disease⁹.

In the current study, we combined data on alcohol consumption with metagenome based taxonomic and functional profiles from participants in a large bowel cancer screening trial in Norway to shed light on this interplay. Specifically, our objectives included: I) investigating associations between alcohol consumption and the occurrence of screening-detected colorectal lesions, II) identifying microbial features linked to alcohol consumption, and III) evaluating whether potential associations between alcohol consumption and colorectal lesions are mediated by the microbiome.

Subjects and Methods

62

83

Study sample

63 Bowel Cancer Screening in Norway (BCSN) and the CRCbiome study 64 The CRCbiome study is nested within the Bowel Cancer Screening in Norway (BCSN) study^{10,11}, a pilot for the Norwegian national screening program. BCSN is a randomized trial 65 66 comparing once-only sigmoidoscopy with four rounds of biennial fecal immunochemical testing 67 (FIT). The BCSN trial was initiated in 2012 and has invited 139,291 women and men to 68 participate. Of these, 70,096 were included in the FIT arm. FIT-positive participants (≥15 µg 69 hemoglobin/g feces) were referred for work-up colonoscopy. 70 The CRCbiome study was initiated in 2017 and has during its four-year recruitment period 71 invited 2,700 participants (starting from the second FIT round). The long-term goal of 72 CRCbiome is to develop a microbiome-based biomarker to improve the current FIT based 73 testing¹¹. FIT-positive participants were invited to CRCbiome in the interval between being 74 informed about their FIT screening result and attending colonoscopy. Besides the invitation 75 letter, participants received two questionnaires to be completed prior to the colonoscopy 76 examination: a food frequency questionnaire (FFQ) and a lifestyle and demographics 77 questionnaire. Returning at least one of these questionnaires was regarded as consent to the 78 study, being fulfilled by 1,640 (61%) participants. The age range at enrollment was 55-77 years. 79 Both the BCSN and the CRCbiome study have been approved by the Regional Committee for 80 Medical Research Ethics in South-East Norway (Approval no.: 2011/1272 and 63148, 81 respectively). The BCSN is also registered at clinicaltrials.gov (Clinical Trial (NCT) no.: 82 01538550).

3

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

The current study included participants from the CRCbiome study with available dietary information (n=1,616). After excluding participants who had withdrawn from the study after inclusion (n=15), not attended colonoscopy (n=39), had a poor quality FFQ (n=21) or reported too low (<600 and <800 kcal/day for women and men, respectively, n=9) or too high (>3,500 and >4,200 kcal/day for women and men, respectively, n=46) energy intake¹², a final number of 1,486 participants were eligible for the study, including 947 individuals with available gut metagenome data (see flowchart, Figure 1). Assessment of alcohol intake Information on dietary intake, including alcohol, was obtained using a self-administered semiquantitative, 14-page FFQ, designed to capture the habitual diet during the preceding year. The questionnaire is a modified version of an FFQ developed by the Department of Nutrition, University of Oslo^{13–19}, which has been validated for a variety of nutrients ^{13,15,18,19} and food groups 15-19, including alcohol intake 13-15. The questionnaire covers a total of 256 food and beverage items, of which eight concern alcoholic beverages (with one additional item covering non-alcoholic drinks). For each beverage type, participants were asked to record frequency of consumption, ranging from never/seldom to several times a week, and amount, typically as standardized alcoholic units. Daily alcohol intake was calculated using the dietary calculation system KBS (short for "Kostberegningssystem"), developed at the Department of Nutrition, University of Oslo. The most recent database at the time, AE-18, was used. AE-18 is an extended version of the official Norwegian Food Composition Table, version 2018²⁰. Alcohol intake was quantified both as ethanol (g/day and energy percentage (E%)) and by alcoholic beverage type (g/day). The alcoholic beverages were categorized as follows (with the standardized unit used in calculations given in brackets): 'Wine', including both red and white wine (15 cl); 'beer',

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

comprising regular and light beer (33 cl); 'spirits', encompassing spirits, mulled wines like port and cherry, and liqueurs (4 cl); and 'drinks', which included cocktails, alcoholic cider, and alcohol-containing soft drinks (20 cl). Additionally, the 'non-alcoholic drinks' category, consisting of non-alcoholic beers (33 cl), was evaluated for comparison purposes. One alcoholic unit was defined as $12 g^{21}$. Prior to analyses, all questionnaires were reviewed and evaluated by trained personnel according to a standardized framework for quality control assessment developed by the study group¹¹. **Outcome assessment** Outcome data were obtained from the BCSN database, containing detailed clinicopathological information on all colorectal lesions detected at work-up colonoscopy. The information was recorded by the responsible endoscopist using a structured reporting system. Based on the most severe finding at colonoscopy, participants were categorized into the following three diagnostic groups: advanced lesions, comprising CRC (any adenocarcinoma of the colon or rectum), advanced adenomas (any adenoma with villous histology, high-grade dysplasia or diameter ≥10 mm) and advanced serrated lesions (any serrated lesion with size ≥10 mm or dysplasia); nonadvanced adenomas; and controls, i.e., no CRC, adenoma nor advanced serrated lesions detected. Sample collection, library generation and shotgun metagenome sequencing Protocols for sample collection, library generation and shotgun metagenome sequencing have been described in detail elsewhere¹¹. In brief, DNA was extracted from 500 µl aliquots, derived from left-over buffer of FIT samples, using the QIAsymphony DSP Virus/Pathogen Midikit (Qiagen, Hilden, Germany), with an offboard lysis protocol based on bead-beating. Purified DNA was further eluted in 60 µl AVE buffer (Qiagen, Hilden, Germany). Following extraction, DNA concentration was measured on Qubit (Thermo Fisher Scientific, MA, USA). For samples

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

with a DNA concentration <1.5 ng/µl, DNA was extracted from a second aliquot. FIT samples with a concentration of 0.7 ng/µl or more were considered eligible for shotgun metagenomic library preparation, whereas for samples with DNA extracted from multiple aliquots, the one with the highest DNA concentration was used. Sequencing libraries were generated according to the Nextera DNA Flex Library Prep Reference Guide, except scaling down the reaction volumes to one fourth of the reference. Library pools of 240 samples were combined and size selected to a fragment size of 650 – 900 bp. Sequencing was performed on the Illumina NovaSeq system (Illumina Inc., CA, USA) using S4 flow cells with lane divider, with each pool sequenced on a single lane resulting in paired end 2 x 151 bp reads. **Determination of taxonomic and functional profiles** Sequencing reads were processed for removal of adapters and low-quality bases using trimmomatic (v0.36)²² with the following trimming options: leading 20, trailing 20, minlength 50. Reads mapping to the human genome (hg38) and PhiX were removed using Bowtie2 (v2.3.5.1)²³. Read-based taxonomy and gene content was assessed using MetaPhlAn3 (v3.0.7) and HumanN3 (v3.0.0)²⁴, respectively, with the mpa v30 ChocoPhlAn 201901 pangenome database, using the UniRef90 database to assign gene families to Metacyc pathways. Read-based taxonomic abundance was evaluated at the species level. Pathway abundance was scaled by the number of quality-controlled reads per million. **Assessment of covariates** Information on covariates was obtained using a self-administered, four-page questionnaire on lifestyle and demographic data, which has been described in detail previously¹¹. The questions relevant to the current study concerned demographic factors (national affiliation, education,

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

occupation and marital status), clinical factors (family history of CRC and diagnosis of chronic bowel disorders) and lifestyle factors (smoking and snus habits and physical activity level). Smokers and snusers were defined as self-reported regular or occasional users or those having quit consumption within the last ten years. Total amount of moderate to vigorous physical activity (minutes/week) was calculated by summing the time spent in moderate and vigorous activity, the latter weighted by a factor of two to best match recent guidelines^{25–27}. Body mass index (BMI) was calculated based on self-reported weight (kg) and height (cm) obtained from the FFQ. **Statistics** Descriptive statistics are presented as median and interquartile range (Q1, Q3) for continuous variables and numbers and percentages for categorical variables. Pairwise correlations between continuous measures were computed using Spearman's correlation coefficients (r). To study the association between alcohol intake and colorectal lesions, multinomial logistic regression analysis was conducted. Colonoscopy findings were categorized into advanced lesions, non-advanced adenomas and controls, according to the outcome definition given above. Alcohol (as ethanol in g/day) was categorized by consumption level (0 g/day, >0-10 g/day, \ge 10-20 g/day and ≥20 g/day) and by adherence to national guidelines (full adherence: 0 g/day, partial adherence: <10 and 20 g/day for women and men, respectively, and non-adherence: ≥10 and 20 g/day for women and men, respectively ^{21,25,28}). Linear (per 10 g/increase/day) and exponential (per 2-fold increase) consumption was evaluated, the latter based on a log2-transformation of the continuous alcohol variable in g/day plus 1 g/day, to enable inclusion of non-consumers in the analysis. For the alcohol subtypes, participants were categorized as consumers/non-consumers.

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

The selection of covariates was based on a priori knowledge on the relationship between alcohol intake and colorectal lesions^{29–31}, with all multinomial logistic regression analyses being adjusted for the following covariates: age (continuous), sex (women, men), national affiliation (Norwegian, non-Norwegian, missing), screening center (center 1, center 2), education level (primary school, high school, college/university, missing), family history of CRC (yes, no, unknown/missing), smoking status (non-smoker, smoker, missing), BMI (continuous, with missing set to median) and level of physical activity (continuous, with missing set to median). Additional adjustment for potential dietary risk or protective factors, such as red and processed meat, whole grain, and dairy products – as well as alternative ways of categorizing covariates, including a more refined smoking variable, were also evaluated, but not included in the final model as they did not influence the interpretation of results. To study potential differential influence of alcohol intake on colorectal lesions by sex, separate analyses were conducted in women and men. Potential interactions were examined using the Wald test. Subgroup analyses were also conducted by precursor lesion subtype (advanced adenoma or advanced serrated lesion) and location (advanced proximal or advanced distal lesion). As sensitivity analyses, the main association analyses were run with alcohol intake calculated as E% rather than g/day, use of a multiple imputation approach for handling of missing data, or the exclusion of participants without metagenome data (n=539). The potential influence of leaving out participants with self-reported bowel disorders (n=216) was also evaluated. To identify microbial features linked to higher alcohol intake, associations of alcohol with the following three measures were examined: α-diversity by means of the Shannon and inverse Simpson indices, β-diversity based on the Bray-Curtis dissimilarity metric, and bacterial species

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

and pathway abundance. Associations with α -diversity were examined using linear regression models with the diversity indices as the dependent variable. To improve normality and ease interpretation, diversity indices were log-transformed prior to analysis. β-diversity was evaluated by principal coordinate analysis (PCoA) and permutational multivariate analysis of variance (PERMANOVA) with 999 permutations. Effect sizes were determined by calculating the partial omega-squared (Ω^2) values. Differential abundance analyses were performed using microbiome multivariable associations with linear models (MaAsLin) 2³² with the following settings: Min. abundance: 0.0; min. prevalence: 0.1; normalization: none and total sum scaling (TSS) for bacteria and pathways, respectively; transformation: log2-transformation with a pseudo-count of half the minimum value; and analyzing method set to a linear model. Benjamini-Hochberg corrected p-values were used as basis for interpretation of results. All analyses on microbial data were conducted in the study group as a whole and stratified by sex. The same set of covariates were adjusted for as in the association analyses with lesions as outcome variable, but with the addition of sequencing depth as a continuous variable. Other combinations of covariates were also evaluated (i.e. the addition of dietary risk or protective factors (as elaborated on above), presence of bowel disorders, as an indicator of bowel movement pattern, and antibiotic usage), but not included in subsequent analyses as they only marginally altered the results. To evaluate whether the gut microbiome mediated the association between alcohol intake and advanced lesions, a causal mediation analysis was applied. An alcohol-associated microbial score was developed as an indicator of the effect of alcohol consumption on the gut microbiome. This score was constructed based on the output of adjusted differential abundance analyses, following the formula proposed by Gevers, et al.³³:

$$score = \log \left(\frac{\sum_{i} s_{i}^{pos}}{\sum_{i} s_{i}^{neg}} \right)$$
 (1)

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

where s_i^{pos} and s_i^{neg} were the abundance of species positively and negatively associated with any level of alcohol consumption, respectively. Zeros in either the numerator or denominator were avoided by substituting zeros with a pseudo-count of half the minimum value of the numerator or denominator across the dataset, respectively. To minimize bias in the estimated effects, a fivefold cross-validation approach was employed for generating the microbial score. Specifically, the dataset was divided into five non-overlapping subsets, where for each subset, a microbial score was calculated using the significantly associated microbial species identified from a fully adjusted differential abundance analysis conducted on the remaining four subsets. The significance threshold for this analysis was set to a Benjamini-Hochberg-adjusted p-value of 0.1. In the causal mediation analysis, 2-fold increases in alcohol intake were treated as the independent variable, advanced lesions as the dependent variable and the alcohol-associated microbial score as the potential mediator. Non-advanced adenomas were grouped with colonoscopy-negatives for these analyses. The mediation analysis was adjusted for the same set of covariates as in the multinomial logistic regression models, as well as the cross-validation partition identity. We used the R package mediation³⁴ and the function 'mediate' based on the following two models: 1) a multivariate linear regression model examining the association between the exposure (E) and the mediator (M), and 2) a multivariate generalized linear model examining the association between the mediator (M) and the outcome (O), controlling for the exposure (E). We report the point estimates along with non-parametric bootstrap confidence intervals using the percentile method. Uncertainty estimates were calculated using 1000 simulations. We also employed the medflex R package³⁵ as an alternative approach to mediation analysis. In this analysis we used a natural effects model with imputation of nested counterfactuals, ensuring that mediation effects were not dependent on covariate levels.

Statistical analyses were performed using R, version 4.1.0 (The R Foundation for Statistical Computing, Vienna, Austria). In addition to packages included in tidyverse (version 1.3.1), main packages, with version number in parentheses, included skimr (2.1.5), corrplot (0.88), nnet (7.3-16), VGAM (1.1-5), mice (3.13.0), vegan (2.5-7), micEco (0.9.15), Maaslin2 (1.12.0), mediation (4.5.0) and medflex (0.6-7).

Results Study population Table 1 shows the key characteristics of the study population overall and by alcohol intake. The median (Q1, Q3) age of participants was 67 (62, 72) years, with a slightly higher representation of men (56%). Compared to non-consumers (13% of participants), those consuming alcohol were more likely to be male and be affiliated to the screening center localized in Bærum (center 2). Higher alcohol intakes were in general positively associated with markers of higher socioeconomic status such as being married or cohabiting, being employed, and holding a university or college degree. The high consumers were also more likely to use snus tobacco and reported having a higher level of physical activity than the non-consumers. Daily intake of alcohol Daily intake of alcohol and different types of alcoholic beverages are presented in **Table 2**. The median (O1, O3) intake of alcohol (as ethanol in g/day) was 9 (2-19) g/day; 13 (4-25) g/day in men and 5 (1-13) g/day in women. Despite higher intakes in men, the proportion adhering to national guidelines was relatively similar between sexes (68% in men, 65% in women). In terms of beverage types, wine was the most frequently consumed by women (74%), whereas beer was the most frequently consumed by men (80%). There were fewer consumers of spirits (30%) and drinks (17%), particularly among women (17 and 13%, respectively). Alcohol (overall and by subtype) was only modestly correlated with energy intake (with Spearman's r's ranging from 0.06-0.24 in the study group as a whole).

Alcohol intake and colorectal lesions

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

Associations between alcohol intake (as ethanol in g/day) and colorectal lesions are shown in **Table 3.** Compared to non-consumption, all levels of alcohol intake, and in particular high levels, were positively associated with advanced lesions ($p_{trend} = 0.008$). The probability of advanced lesions increased by 9% per 10 g increase/day and 14% per 2-fold increase/day. Partial and non-adherence to guidelines were also positively associated with advanced lesions relative to not consuming alcohol, with odds ratios (ORs) of 1.91 (95% confidence intervals (CI) 1.22, 2.99) and 1.97 (1.23, 3.17), respectively. Notable differences were observed between women and men, with associations being consistently stronger for women. As an example, relative to those not consuming alcohol, women in the highest consumption category (≥ 20 g/day) had an OR for advanced lesions of 4.81 (95% CI 2.18, 10.62) compared to 1.48 (0.74, 2.96) in men ($p_{interaction} =$ 0.040). No associations between alcohol intake and non-advanced adenomas were detected. Subgroup analyses by lesion subtype and location implied associations for both groups of precursor lesions, regardless of lesion location (Supplementary Table 1). Sensitivity analyses with alcohol intake as E%, use of a multiple imputation approach for handling of missing values and restricting the study population to those with metagenome data only (Supplementary Tables 2-4) produced similar results as in the main analyses. This was also the case for an analysis excluding participants with a self-reported bowel disorder (data not shown). In terms of beverage types, positive associations with advanced lesions were seen for consumers of wine (OR 1.41; 95%CI 1.03, 1.92) and beer (OR 1.31; 0.97, 1.77; **Figure 2**). Stratifying the analyses by sex, the association for wine was stronger (and only statistically significant) in women, whereas the association for beer tended to be stronger for men (although not statistically significant). No associations with non-advanced adenomas were observed.

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

Alcohol intake and gut microbial features Metagenome shotgun sequencing data derived from leftover buffer containing fecal matter collected in screening FIT cartridges was available for 947 participants (mean = 12 million paired end reads, sd = 3.8 million). Taxonomic classification resulted in identification of a total of 787 microbial species (mean = 88, sd = 15.5 per sample). α-diversity Associations of alcohol intake with the α-diversity indices Shannon and Inverse Simpson are presented in Figure 3a-c and Supplementary Table 5. In general, there was a weak, but statistically significant positive association between alcohol intake (as ethanol in g/day) and both diversity indices. The shift in diversity became noticeable already at low intake levels. Compared to the non-consumers, those consuming alcohol had a 2.7 and 10.2% higher Shannon and Inverse Simpson index, respectively. No dose-response associations were observed. Stratification by sex showed the associations between total alcohol intake and α -diversity to be statistically significant in women only. Still, looking at alcoholic beverage subtypes, statistically significant positive associations were observed for consumers of beer (overall and in men), wine (women), spirits (overall and in women) and non-alcoholic drinks (women). As for ethanol in g/day, there were no clear dose-response relationships. β-diversity Associations of alcohol intake with the Bray-Curtis β-diversity index are presented in Figure 3dg and Supplementary Table 5. Irrespective of the approach to quantifying alcohol intake (as ethanol in g/day), the microbial composition differed by intake level (Ω values of 0.0005-0.0010, PERMANOVA-derived p-values <0.05, Supplementary Table 5). Consumers of alcohol

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

displayed a small shift in microbial composition (Figure 3d), and were less heterogeneous (Figure 3e) than the non-consumers. There was, however, no difference in microbial composition by intake level (data not shown). Consuming alcohol was associated with microbial composition regardless of sex. Consumption of wine, and to a lesser extent, beer, seemed to be related to microbial composition (Figure 3f). Differentially abundant bacteria and pathways Associations between alcohol intake and bacteria and pathway abundance are presented in **Figures 4a** and **5a**. In total, 6 bacteria (2 positively and 4 negatively) and 7 pathways (5 positively and 2 negatively) were statistically significantly associated with at least one of the alcohol consumption categories (Figures 4a and 5a). Of those predictive of the highest consumption category, 4 out of 5 bacteria (i.e. L. asaccharolyticus, B. finegoldii, S. mutans and C. symbiosum) and 3 out of 4 pathways (i.e. the tricarboxylic acid (TCA) cycle II, superpathway of sulfur oxidation and L-lysine biosynthesis II), remained statistically significant after mutual adjustment for the other bacteria and pathways, respectively (Supplementary Figure 2a). Several of the identified bacteria and pathways were inter-correlated (Supplementary Figure 2b). None of the identified bacteria or pathways showed signs of interaction with sex (separate analyses for women and men can be found in **Supplementary Figure 3**). With regard to consumption of different alcoholic beverages (Figure 4b and 5b), beer was statistically significantly associated with 4 pathways (the superpathway of sulfur oxidation, Lglutamate degradation via hydroxyglutarate, ppGpp biosynthesis and L-lysine biosynthesis), wine with 3 bacteria (L. asaccharolyticus, S. mutans and B. dentium) and 2 pathways (L-lysine

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

biosynthesis and succinate fermentation to butanoate), and spirits with 1 bacterium (F. bacterium GAG 95) and 1 pathway (L-glutamate and L-glutamine biosynthesis). For the other beverage types, no statistical differences were detected. The gut microbiome as a potential mediator Based on output from differential abundance analysis, an alcohol-associated microbial score was developed to examine the potential mediating role of alcohol-related bacteria in colorectal carcinogenesis (see Supplementary Tables 6-7 for bacterial species significantly associated with alcohol intake overall and using the previously described five-fold cross-validation approach). The causal mediation analysis showed that the alcohol-associated microbial score partially mediated the association between alcohol intake and advanced colorectal lesions (Figure 6a). The total effect (95% CI) of alcohol on advanced lesions was 0.033 (0.017, 0.047), the average direct effect (ADE) was 0.029 (0.012, 0.043) and the average causal mediation effect (ACME) was 0.004 (0.001, 0.008). Overall, the proportion mediated was 12.1% (3.1, 32.2; Figure 6b), confirmed using an approach based on nested counterfactuals (here the proportion mediated was 12.2%, **Supplementary Table 8**). To assess potential differences in mediation effects between women and men while maintaining power, we conducted a mediation analysis omitting sex as a covariate. This did, however, only marginally affect the results.

Discussion

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

This study provides new evidence on the detrimental role of alcohol in the development of colorectal lesions. We found a positive association between alcohol consumption and advanced colorectal lesions detected at screening even at modest intake levels. This association was strong in the overall population and in women, while no clear association was observed in men. Consumers of alcohol had a distinct gut microbial profile, characterized by higher species diversity, altered microbial composition and differentially abundant bacteria and pathways. This distinctive microbial profile partly explained the association between alcohol intake and advanced lesions observed. Our results support a role of the microbiome in alcohol-induced colorectal carcinogenesis. In the present study, every 10 g per day increase in alcohol consumption was associated with a 9% increased probability of advanced lesions being detected at colonoscopy, consistent across lesion subtype and location. Our results are in line with the literature on precancerous colorectal lesions. Meta-analyses have demonstrated a 27% increased risk of adenoma per 25 g alcohol consumed per day³⁶, along with comparable increases in the risk of serrated polyps^{37,38}. Together, these results coincide with the literature on alcohol and CRC^{29,39,40}. In our study, consumption levels even below 10 g/day were associated with advanced lesions. As such, our findings reinforce cancer prevention guidelines of complete abstinence to achieve the lowest possible risk⁴¹. The stronger association observed in women compared to men contrasts with prior literature. In the CUP 2016 meta-analysis from WCRF/AICR²⁹, as well as two pooled analyses (from UK and Japan, respectively)^{42,43}, no particular heterogeneity was found between sexes. Women from

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

Europe and Australia have the highest per-capita alcohol consumption worldwide, surpassing the global average by a factor of about two⁵. It is noteworthy that these regions also bear the highest incidence rates of CRC among women. Norway ranking at the top in 2020⁴⁴. The consumption pattern of participants included in the present study seems to mirror those of the general Norwegian population 45,46. Whether country-specific trends in alcohol consumption may account for divergence in findings remains a matter of speculation. Our study demonstrated notable differences in the gut microbiome of participants consuming relative to not consuming alcohol, potentially of relevance to tumorigenesis. A link between alcohol intake and gut microbiome perturbations has been documented by others^{47–51}. However, this has typically been studied in the context of chronic alcoholism 47,48,50 and/or presence of severe liver pathologies^{48,49} that could confound the alcohol-gut microbiome relationship. We observed that even modest alcohol consumption was associated with an increase in α - and a convergence of β-diversity. The diversity change has also been reported in studies of other Western populations^{52–55}, revealing alcohol as a strong source of gut microbiome variation. We identified four bacterial species to be independently associated with alcohol consumption: L. asaccharolyticus and B. finegoldii were positively associated, whereas C. symbiosum and S. mutans were negatively associated. These results reproduce associations reported in the PREDICT study, which assessed microbial relationships with habitual diet in a large population, also finding L. asaccharolyticus and C. symbiosum to be strong determinants of alcohol consumption⁵⁵. Among the identified bacteria, C. symbiosum has earlier been suggested as a potential biomarker for CRC^{56,57}. Interestingly, we found the association between alcohol consumption and detection of advanced lesions to be partially mediated by the gut microbiome. The mediated proportion was a modest,

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

but conservative, 12% of the total effect, but nonetheless suggests that microbial changes caused by alcohol consumption could contribute to CRC development. How the relatively small concentrations of ethanol reaching the large intestine can induce microbial changes of relevance to carcinogenic development is however unclear. A conventional belief has been that the intestinal bacteria play an important role in metabolizing the remaining amounts of ethanol, through bacterial catalases and ADH activity, leading to accumulation of acetaldehyde and thus causing local damage^{7,8,58}. However, this was recently questioned by Martino, et al.⁶ who used a mouse model to demonstrate that rather than metabolizing ethanol directly, gut bacteria responded to ethanol-feeding by activating acetate dissimilation. In line with these findings, we observed that TCA cycle gene abundance was positively associated with alcohol consumption. Acetate has recently received renewed attention in the context of CRC⁷. Although historically being regarded as protective, recent evidence suggests that acetate may contribute to cancer cell growth by serving as a substrate for the synthesis of acetyl-CoA⁷. We also found alcohol consumption to be associated with increased abundance of sulfur oxidation superpathway genes, regardless of consumption levels. Sulfur metabolism is characteristic of a wide range of bacteria⁵⁹ and has been associated with CRC⁵⁹ and other gut disorders⁶⁰. In combination, these results suggest a potential for alcohol consumption to increase risk of CRC via bacterial acetate and sulfur metabolism. A major strength of our study includes its large set of microbiome samples obtained through state-of-the-art methodology, coupled with validated exposure information. Access to clinically verified outcome data facilitated thorough investigations of screening-relevant outcomes, with minimal risk of misclassification. With a study population solely consisting of FIT positive participants, the proportion of detected lesions was high (63%). Nonetheless, this selective

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

inclusion of participants may have restricted the generalizability of our findings. Other limitations must also be considered. First, the cross-sectional design limits causal interpretations, and the results must be viewed as hypothesis-generating only. Thus, although access to comprehensive data on lifestyle and demography allowed for detailed covariate adjustment (being particularly unique for the microbiome analyses), we cannot exclude the possibility of residual or reverse confounding. Second, selective inclusion of participants with colon bleeding at specimen collection, could have introduced bias. The proportion of participants with gastrointestinal morbidity may have been unevenly distributed between alcohol intake and outcome categories. This may be of particular concern for the present study, as some overrepresentation of former drinkers and "sick quitters" among the non-consumers, is to be expected⁶¹. However, excluding participants with self-reported gastrointestinal morbidity did not alter the observed associations. To conclude, our study confirms the role of alcohol in the etiology of CRC. Consistent and positive associations were observed between alcohol consumption and advanced lesions even at moderate consumption levels, and particularly in women. Consuming alcohol was associated with a distinct microbial profile in the gut, manifested as increased species diversity, altered microbial composition and differentially abundant bacteria and pathways. Collectively, alcoholassociated bacteria mediated 12% of the association between alcohol intake and advanced colorectal lesions. The potential role of alcohol-associated microbial alterations in cancer development should be further examined in prospective cohort studies with long-term follow-up. Such studies should investigate potential sex differences and ideally expand the repertoire of biological mechanisms by evaluating metabolic, inflammatory, and immune-modulatory pathways.

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

Acknowledgements We would like to thank the devoted healthcare personnel, technicians and administrative staff at the two screening centers (Moss center and Bærum center) and university hospitals (Oslo University Hospital and Akershus University Hospital) for their important contributions to the BSCN and CRCbiome study. We offer special thanks to Jan Inge Nordby and Vahid Bemanian for their instrumental role in sample preparation and laboratory work. Library preparation and sequencing were carried out at the FIMM Technology Centre supported by HiLIFE and Biocenter Finland. We would particularly express our gratitude to Harri A. Kangas and Pekka J. Ellonen for their good cooperation, service and support. All processing of dietary data, including food and nutrient calculations, was conducted at the Department of Nutrition, University of Oslo. We would particularly like to thank Anne Marte Wetting Johansen for her dedicated work and attention to detail. Lastly, this article is the outcome of collective teamwork and scientific discussions among both former and current colleagues within our research group. Therefore, we would like to acknowledge Elina Vinberg, Even Sannes Riiser, Erik Natvig, Paula Istvan and Maja Jacobsen for their valuable contributions. **Conflict of Interest (COI) Statement:** Dr. Mingyang Song serves as a consultant for Etiome Inc. The remaining authors declare no conflicts of interest.

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

Authors' contributions ASK, EB, EB, CBJ, TBR and PB designed the research (project conception, development of overall research plan, and study oversight). ASK, EB, EA, CBJ, KRR, TBR and PB conducted the research (hands-on conduct of the experiments and data collection). ASK, EB, CBJ, AH, KRR, GH, TBR and PB provided essential materials (applies to authors who contributed by providing animals, constructs, databases, etc, necessary for the research). ASK, EB, CBJ and EB analyzed data or performed statistical analysis. ASK wrote the paper (only authors who made a major contribution). ASK and PB had the primary responsibility for the final content. ASK, EB, EA, EB, CBJ, MDK, AH, CMP, JRH, MS, KRR, GH, TNR and PB have read and approved the final manuscript. Data availability DNA sequencing data analyzed in this study are deposited in the database Federated EGA under accession code EGAS50000000170 (https://ega-archive.org/studies/EGAS50000000170). Per participant consent, submitted FASTO files exclude reads mapping to the human genome. The data are available under restricted access due to the sensitive nature of data derived from human subjects. Processing of data from this study must comply with the General Data Protection Regulation (GDPR). Access can be obtained by following the procedure described here: https://www.mn.uio.no/sbi/english/groups/roungegroup/crcbiome/. Requests for data access can also be directed to Trine B Rounge, trinro@uio.no.

Declaration of generative AI and AI-assisted technologies in the writing process

491

492

493

494

During the preparation of this work the first author(s) used Chat-GTP in order to improve

language and readability. After using this tool/service, the author(s) reviewed and edited the

content as needed and take(s) full responsibility for the content of the publication.

References

- 1. World Cancer Research Fund/American Institute for Cancer Research. Alcoholic drinks and the risk of cancer. *Continous Updat. Proj.* (2018).
- 2. LoConte, N. K., Brewster, A. M., Kaur, J. S., Merrill, J. K. & Alberg, A. J. Alcohol and cancer: A statement of the American society of clinical oncology. *J. Clin. Oncol.* **36**, 83–93 (2018).
- 3. Scherübl, H. Alcohol Use and Gastrointestinal Cancer Risk. *Visc. Med.* **36**, 175–181 (2020).
- 4. Rumgay, H. *et al.* Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. *Lancet Oncol.* **22**, 1071–1080 (2021).
- 5. Manthey, J. *et al.* Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. *Lancet* **393**, 2493–2502 (2019).
- 6. Martino, C. *et al.* Acetate reprograms gut microbiota during alcohol consumption. *Nat. Commun.* **13**, (2022).
- 7. Johnson, C. H. *et al.* Molecular mechanisms of alcohol-induced colorectal carcinogenesis. *Cancers* vol. 13 at https://doi.org/10.3390/cancers13174404 (2021).
- 8. Song, M. & Chan, A. T. Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention. *Clinical Gastroenterology and Hepatology* vol. 17 275–289 at https://doi.org/10.1016/j.cgh.2018.07.012 (2019).
- 9. Tilg, H., Adolph, T. E., Gerner, R. R. & Moschen, A. R. The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell* **33**, 954–964 (2018).
- 10. Randel, K. R. *et al.* Colorectal cancer screening with repeated fecal immunochemical test versus sigmoidoscopy: baseline results from a randomized trial. *Gastroenterology* (2020) doi:10.1053/j.gastro.2020.11.037.
- 11. Kværner, A. S. *et al.* The CRCbiome study: A large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants. *medRxiv* (2020) doi:10.1101/2020.12.22.20248658.
- 12. Willett, W. *Nutritional Epidemiology*. (Oxford University Press, Oxford; New York, 2013).
- 13. Andersen, L. F. *et al.* Evaluation of a food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose tissue and serum. *Am. J. Epidemiol.* **150**, 75–87 (1999).
- 14. Andersen, L. F., Tomten, H., Haggarty, P., Løvø, A. & Hustvedt, B. E. Validation of energy intake estimated from a food frequency questionnaire: A doubly labelled water study. *Eur. J. Clin. Nutr.* **57**, 279–284 (2003).
- 15. Carlsen, M. H. *et al.* Evaluation of energy and dietary intake estimates from a food frequency questionnaire using independent energy expenditure measurement and weighed food records. *Nutr. J.* **9**, 1–9 (2010).

- 16. Andersen, L. F. *et al.* Evaluation of three dietary assessment methods and serum biomarkers as measures of fruit and vegetable intake, using the method of triads. *Br. J. Nutr.* **93**, 519–527 (2005).
- 17. Carlsen, M. H. *et al.* Relative validity of fruit and vegetable intake estimated from an FFQ, using carotenoid and flavonoid biomarkers and the method of triads. *Br. J. Nutr.* **105**, 1530–1538 (2011).
- 18. Brunvoll, S. H. *et al.* Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment. *Nutr. J.* 17, 1–12 (2018).
- 19. Nes, M. *et al.* Accuracy of a quantitative food frequency questionnaire applied in elderly Norwegian women. *Eur. J. Clin. Nutr.* (1992).
- 20. Norwegian Food Safety Authority. Norwegian Food Composition Database 2019. www.matvaretabellen.no.
- 21. Nordic Council of Ministers. *Nordic Nutrition Recommendations* 2012 *Integrating Nutrition and Physical Activity.* 5th Ed. (2012) doi:10.1080/1102680410003794.
- 22. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
- 23. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
- 24. Beghini, F. *et al.* Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with biobakery 3. *Elife* **10**, 1–42 (2021).
- 25. Helsedirektoratet. *Anbefalinger Om Kosthold*, *Ernæring Og Fysisk Aktivitet*. https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/806/Anbefalinger-om-kosthold-ernering-og-fysisk-aktivitet-IS-2170.pdf (2014).
- 26. World Health Organization (WHO). *Global Recommendations on Physical Activity for Health*. (2010).
- 27. U.S. Department of Health and Human Services. *Physical Activity Guidelines for Americans*. (2018).
- 28. Blomhoff, R., Andersen, R., Arnesen, E.K., Christensen, J.J., Eneroth, H., Erkkola, M., Gudanaviciene, I., Halldorsson, T.I., Høyer-Lund, A., Lemming, E.W., Meltzer, H.M., Pitsi, T., Schwab, U., Siksna, I., Thorsdottir, I. and Trolle, E. *Nordic Nutrition Recommendations* 2023. *Integrating Environmental Aspects.* 6th Ed. (2023).
- 29. World Cancer Research Fund/American Institute for Cancer Research. *Diet, Nutrition, Physical Activity and Colorectal Cancer. Continuous Update Project* https://www.wcrf.org/sites/default/files/Colorectal-cancer-report.pdf (2018).
- 30. Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. *Lancet (London, England)* **394**, 1467–1480 (2019).
- 31. Kuipers, E. J. et al. Colorectal cancer. Nat. Rev. Dis. Prim. 1, (2015).

- 32. Mallick, H. *et al.* Multivariable association discovery in population-scale meta-omics studies. *PLoS Comput. Biol.* **17**, 1–27 (2021).
- 33. Gevers, D. *et al.* The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe* **15**, 382–392 (2014).
- 34. Tingley, D., Yamamoto, T., Hirose, K., Keele, L. & Imai, K. Mediation: R package for causal mediation analysis. *J. Stat. Softw.* **59**, 1–38 (2014).
- 35. Steen, J. & Loeys, T. Medflex□: An R Package for Flexible Mediation Analysis using Natural Effect Models. (2010).
- 36. Ben, Q. *et al.* Alcohol drinking and the risk of colorectal adenoma: A dose-response meta-analysis. *Eur. J. Cancer Prev.* **24**, 286–295 (2015).
- 37. Bailie, L., Loughrey, M. B. & Coleman, H. G. Lifestyle Risk Factors for Serrated Colorectal Polyps: A Systematic Review and Meta-analysis. *Gastroenterology* **152**, 92–104 (2017).
- 38. Wang, Y.-M. *et al.* Systematic Review with Meta-Analysis: Alcohol Consumption and Risk of Colorectal Serrated Polyp. *Dig. Dis. Sci.* **60**, 1889–1902 (2015).
- 39. Lyon, F. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans VOLUME 96 Alcohol Consumption and Ethyl Carbamate.* (2010).
- 40. Weiderpass, E. & Stewart, B. W. World Cancer Report.
- 41. World Cancer Research Fund/American Institute for Cancer Research. *Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. Continuous Update Project Expert Report 2018* (2018). doi:10.1016/j.scienta.2014.02.005.
- 42. Park, J. Y. *et al.* Alcohol intake and risk of colorectal cancer: Results from the UK Dietary Cohort Consortium. *Br. J. Cancer* **103**, 747–756 (2010).
- 43. Mizoue, T. *et al.* Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. *Am. J. Epidemiol.* **167**, 1397–1406 (2008).
- 44. Ferlay, J. *et al.* Global Cancer Observatory: Cancer Today. vol. 2024 https://gco.iarc.who.int/today (2024).
- 45. Folkehelseinstituttet. Alkohol i Norge. https://www.fhi.no/le/alkohol/alkoholinorge/?term= (2018).
- 46. Helsedirektoratet. *Norkost 3. En Landsomfattende Kostholdsundersøkelse Blant Menn Og Kvinner i Norge i Alderen 18-70 År, 2010-11.* www.helsedirektoratet.no (2012).
- 47. Tsuruya, A. *et al.* Ecophysiological consequences of alcoholism on human gut microbiota: Implications for ethanol-related pathogenesis of colon cancer. *Sci. Rep.* **6**, 1–12 (2016).
- 48. Dubinkina, V. B. *et al.* Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. *Microbiome* **5**, (2017).
- 49. Chen, Y. *et al.* Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology* **54**, 562–572 (2011).

- 50. Day, A. W. & Kumamoto, C. A. Gut Microbiome Dysbiosis in Alcoholism: Consequences for Health and Recovery. *Front. Cell. Infect. Microbiol.* **12**, 1–10 (2022).
- 51. Pohl, K., Moodley, P. & Dhanda, A. D. Alcohol's impact on the gut and liver. *Nutrients* **13**, (2021).
- 52. Zhernakova, A. *et al.* Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science* (80-.). **352**, 565–569 (2016).
- 53. Falony, G. *et al.* Population-level analysis of gut microbiome variation. *Science* (80-.). **352**, 560–564 (2016).
- 54. Vujkovic-cvijin, I. *et al.* Host variables confound gut microbiota studies of human disease. *Nature* **587**, (2020).
- 55. Asnicar, F. *et al.* Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. *Nat. Med.* **27**, 321–332 (2021).
- 56. Thomas, A. M. *et al.* Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. *Nat Med* **25**, 667–678 (2019).
- 57. Xie, Y. H. *et al.* Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies. *EBioMedicine* **25**, 32–40 (2017).
- 58. Rossi, M., Anwar, M. J., Usman, A., Keshavarzian, A. & Bishehsari, F. Colorectal cancer and alcohol consumption—populations to molecules. *Cancers (Basel)*. **10**, (2018).
- 59. Wolf, P. G. *et al.* Diversity and distribution of sulfur metabolic genes in the human gut microbiome and their association with colorectal cancer. *Microbiome* **10**, 1–16 (2022).
- 60. Khorsand, B. *et al.* Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn's disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets. *Front. Cell. Infect. Microbiol.* **12**, 1–11 (2022).
- 61. Zhao, J. *et al.* Association between Daily Alcohol Intake and Risk of All-Cause Mortality: A Systematic Review and Meta-analyses. *JAMA Netw. Open* **6**, E236185 (2023).
- 62. Nasjonalt råd for ernæring. Kostråd for å Fremme Folkehelsen Og Forebygge Kroniske Sykdommer Metodologi Og Vitenskapelig Kunnskapsgrunnlag. (2011).

Tables

Table 1. Key characteristics of the study population overall and by alcohol intake (n=1,486)¹.

<u> </u>	Level of alcohol intake							
	n	Overall	0 g/day	>0-10 g/day	≥10-20 g/day	≥20 g/day		
Variables		(n=1,486)	(n=187)	(n=592)	(n=361)	(n=346)		
Age, years	1,486	67 (62, 72)	67 (62, 73)	67 (62, 72)	66 (62, 72)	68 (62, 72)		
Male sex, n (%)	1,486	826 (55.6)	70 (37.4)	281 (47.5)	212 (58.7)	263 (76.0)		
Screening center, n (%)	1,486	` ,	,	, ,	` ,	,		
Center 1 (Moss)		774 (52.1)	135 (72.2)	323 (54.6)	166 (46.0)	150 (43.4)		
Center 2 (Bærum)		712 (47.9)	52 (27.8)	269 (45.4)	195 (54.0)	196 (56.6)		
National affiliation, n (%)	1,427	` ,	` ,	` ,	` ,	, ,		
Norwegian		1345 (94.3)	160 (89.4)	540 (94.7)	333 (96.0)	312 (94.3)		
Non-Norwegian		82 (5.7)	19 (10.6)	30 (5.3)	14 (4.0)	19 (5.7)		
Family history of CRC, n (%)	1.347							
No		1,092 (81.1)	133 (83.1)	442 (81.1)	272 (83.2)	245 (77.8)		
Yes		255 (18.9)	27 (16.9)	103 (18.9)	55 (16.8)	70 (22.2)		
Marital status, n (%)	1,465							
Married/cohabiting		1,171 (79.9)	123 (67.6)	460 (79.0)	308 (85.8)	280 (81.9)		
Not married/non-cohabiting		294 (20.1)	59 (32.4)	122 (21.0)	51 (14.2)	62 (18.1)		
Education, n (%)	1,462							
Primary school		251 (17.2)	54 (29.8)	102 (17.5)	50 (14.0)	45 (13.2)		
High school		580 (39.7)	75 (41.4)	243 (41.8)	144 (40.2)	118 (34.6)		
University/college		631 (43.2)	52 (28.7)	237 (40.7)	164 (45.8)	178 (52.2)		
Working status, n (%)	1,464							
Employed		498 (34.0)	40 (22.1)	190 (32.6)	140 (39.1)	128 (37.4)		
Retired/unemployed		966 (66.0)	141 (77.9)	393 (67.4)	218 (60.9)	214 (62.6)		
Bowel disorder, n(%)	1,451							
No bowel disease		1,235 (85.1)	147 (82.6)	482 (84.0)	300 (83.8)	306 (89.7)		
IBS		81 (5.6)	10 (5.6)	30 (5.2)	31 (8.7)	10 (2.9)		
Celiac disease		18 (1.2)	3 (1.7)	8 (1.4)	4 (1.1)	3 (0.9)		
IBD		24 (1.7)	5 (2.8)	11 (1.9)	7 (2.0)	1 (0.3)		
Other		93 (6.4)	13 (7.3)	43 (7.5)	16 (4.5)	21 (6.2)		
Smoking status ² , n (%)	1,462							
Non-smoker		1,082 (74.0)	127 (70.2)	438 (75.3)	270 (75.4)	247 (72.4)		
Smoker		380 (26.0)	54 (29.8)	144 (24.7)	88 (24.6)	94 (27.6)		
Snus status ³ , n(%)	1,405							
Non-snuser		1,308 (93.1)	171 (97.2)	530 (95.3)	318 (92.4)	289 (87.8)		
Snuser		97 (6.9)	5 (2.8)	26 (4.7)	26 (7.6)	40 (12.2)		
BMI, kg/m ²	1,480	26 (24, 29)	27 (25, 30)	26 (24, 29)	26 (24, 29)	27 (24, 29)		
Physiscal activity, min/week	1,466	135 (0, 300)	45 (0, 195)	135 (0, 300)	180 (15, 390)	180 (45, 352)		
Questionnaires completed	1,486							
prior to colonoscopy, n(%)								
No		126 (8.5)	15 (8.0)	42 (7.1)	30 (8.3)	39 (11.3)		
Yes		1,360 (91.5)	172 (92.0)	550 (92.9)	331 (91.7)	307 (88.7)		

Values are median (Q1, Q3) for continuous variables and n (%) for categorical variables.

Abbreviations: BMI; Body mass index, CRC; colorectal cancer, g; gram, n; number

^{2,3}To be defined as a smoker or snuser one had to be a regular or occasional user or having quit consumption within the last ten years.

Table 2. Alcohol consumption in the study population as a whole (n=1,486) and by sex (660 women, 826 men).

	Percentiles Percentiles			s	Adherent to guidelines ¹	Zero consumers	Correlation with energy intake
	25	50	75	100	n (%)	n (%)	$r_{\rm s}^2$
Overall							-
Alcohol, g/day	2.2	9.0	19	195	991 (67)	187 (13)	0.22**
Alcohol, E%	0.7	2.9	6.0	45	1003 (68)	187 (13)	-0.04
Alcohol units ³ /day	0.2	0.7	1.6	16	1083 (73)	187 (13)	0.22**
Alcohol subtypes, g/day							
Beer	0.0	33	140	3743	-	535 (36)	0.24**
Wine	0.0	36	108	837	-	417 (28)	0.06*
Spirits	0.0	0.0	1.2	223	-	1040 (70)	0.11**
Drinks, cider, etc.	0.0	0.0	0.0	768	-	1240 (83)	0.10**
Non-alcoholic drinks, g/day	0.0	0.0	14	2000	-	1100 (74)	0.13**
Men							
Alcohol, g/day	3.8	13	25	195	563 (68)	70 (8)	0.17**
Alcohol, E%	1.2	3.6	7.2	45	503 (61)	70 (8)	-0.10*
Alcohol units ³ /day	0.3	1.1	2.1	16	610 (74)	70 (8)	0.17**
Alcohol subtypes, g/day							
Beer	16	80	203	3743	-	167 (20)	0.19**
Wine	0	35	108	837	-	247 (30)	0.04
Spirits	0	0	4,8	223	-	489 (59)	0.07
Drinks, cider, etc.	0	0	0	768	-	667 (81)	0.07*
Non-alcoholic drinks, g/day	0	0	14	2000	-	591 (72)	0.11*
Women							
Alcohol, g/day	1.1	5.4	13	87	428 (65)	117 (18)	0.13*
Alcohol, E%	0.4	2.0	4.8	34	500 (76)	117 (18)	-0.12*
Alcohol units ³ /day	0.1	0.5	1.1	7.23	473 (72)	117 (18)	0.13*
Alcohol subtypes, g/day							
Beer	0.0	0.0	45	1280	-	368 (56)	0.11*
Wine	0.0	41	108	837	-	170 (26)	0.09*
Spirits	0.0	0.0	0.0	78	-	549 (83)	0.04
Drinks, cider, etc.	0.0	0.0	0.0	288	-	571 (87)	0.08
Non-alcoholic drinks, g/day	0	0	0	500	-	511 (77)	0.19**

^{1&}lt;10 g/day for women and <20 g/day for men according to Nordic and national nutritional reccommendations^{21,25}; <5 energy percentage (E%) for both sexes according to Nordic and national nutritional reccommendations^{21,25}; <1 unit for women and <2 units for men according to national food-based dietary guidelines⁶².

2**<0.001, *<0.05.

Abbreviations: E%; energy percentage, n; number, r_s ; Spearman's correlation coefficient.

³I unit set to 12 grams in line with national guidelines^{21,25}.

Table 3. Odds ratios (ORs) and 95% confidence intervals (CIs) for presence of non-advanced adenoma¹ and advanced lesions² relative to controls by level of alcohol consumption in the study population as a whole (n=1,486) and by sex (660 women, 826 men)^{3,4}.

and by sex (660 women, 826 men)	Control Non-advanced adenoma (n=548) (n=524)		Advanced lesions (n=414)		
	<u>n</u>	<u>n</u>	OR (95% CI)	<u>n</u>	OR (95% CI)
Overall	_				
Level of intake					
0 g/day	88	65	Ref.	34	Ref.
>0-10 g/day	226	202	1.16 (0.79, 1.70)	164	1.81 (1.15, 2.85)
≥10-20 g/day	126	131	1.31 (0.86, 2.00)	104	1.99 (1.22, 3.27)
≥20 g/day	108	126	1.30 (0.84, 2.02)	112	2.19 (1.32, 3.63)
p_{trend}			0.20		0.008
Per 10 g increase/day			1.03 (0.94, 1.12)		1.09 (1.00, 1.19)
Pcont			0.52		0.047
Per 2-fold increase/day			1.03 (0.96, 1.11)		1.14 (1.05, 1.23)
Pcont			0.42		0.002
Adherence to guidelines					
Fully adhering (0 g/day)	88	65	Ref.	34	Ref.
Partially adhering (<10/20 g/day)	291	275	1.16 (0.80, 1.70)	238	1.91 (1.22, 2.99)
Not adhering (≥10/20 g/day)	169	184	1.34 (0.89, 2.00)	142	1.97 (1.23, 3.17)
Men					
Level of intake	-				
0 g/day	31	22	Ref.	17	Ref.
>0-10 g/day	87	111	1.58 (0.84, 2.97)	83	1.55 (0.78, 3.06)
≥10-20 g/day	65	73	1.37 (0.71, 2.67)	74	1.92 (0.95, 3.88)
≥20 g/day	84	99	1.32 (0.69, 2.51)	80	1.48 (0.74, 2.96)
Ptrend			0.99		0.48
Per 10 g increase/day			1.00 (0.91, 1.11)		1.04 (0.95, 1.15)
Pcont			0.92		0.37
Per 2-fold increase/day			0.99 (0.89, 1.09)		1.08 (0.98, 1.21)
Pcont			0.81		0.13
Adherence to guidelines					
Fully adhering (0 g/day)	31	22	Ref.	17	Ref.
Partially adhering (<20 g/day)	152	184	1.49 (0.81, 2.74)	157	1.69 (0.88, 3.25)
Not adhering (≥20 g/day)	84	99	1.32 (0.69, 2.52)	80	1.47 (0.74, 2.93)
Women					
Level of intake	-				
0 g/day	57	43	Ref.	17	Ref.
>0-10 g/day	139	91	0.96 (0.58, 1.58)	81	2.07 (1.10, 3.90)
≥10-20 g/day ≥10-20 g/day	61	58	1.46 (0.82, 2.57)	30	1.80 (0.87, 3.73)
≥10-20 g/day ≥20 g/day	24	27	1.65 (0.81, 3.35)	32	4.81 (2.18, 10.62)
	57	43	0.05	17	0.001
Per 10 g increase/day	31	43	1.09 (0.91, 1.30)	1 /	1.27 (1.06, 1.52)
Pcont			0.36		0.010
Per 2-fold increase/day			1.09 (0.97, 1.22)		1.22 (1.08, 1.39)
Pcont			0.13		0.002
Adherence to guidelines					
Fully adhering (0 g/day)	57	43	Ref.	17	Ref.
Partially adhering (<10 g/day)	139	91	0.96 (0.58, 1.58)	81	2.09 (1.11, 3.93)
Not adhering (≥10 g/day)	85	85	1.51 (0.89, 2.57)	62	
TYOU AUTHERING (<10 g/day)	63	83	1.31 (0.89, 2.37)	02	2.66 (1.37, 5.19)

¹Includes any adenoma (adenomatous polyp) not fulfilling the criteria of being advanced.


²Includes advanced adenoma, defined as any adenoma with either villous histology (≥25% villous components), high-grade dysplasia or polyp size greater than or equal to 10 mm; advanced serrated lesions, defined as any serrated lesions with size ≥ 10 mm or dysplasia; and colorectal cancer, defined as presence of adenocarcinoma arising from the colon or rectum.


³Odds ratios (ORs) and 95% confidence intervals (CIs) are obtained from multinomial logistic regression analyses adjusting for the following covariates: age (continuous), sex (except in the sex-specific analyses), national affiliation (Norwegian affiliation, non-Norwegian affiliation, missing), screening center (center 1, center 2), education level (primary school, high school, college/university, missing), family history of CRC (yes, no, unknown/missing), smoking status (non-smoker, smoker, missing), BMI (continuous with missing set to median) and level of physical activity (continuous with missing set to median).


⁴Potential interactions of alcohol intake with sex was examined using the Wald test, resulting in the following p-values: 'Level of intake' (p-values in sequential order (2-4): 0.57, 0.82, 0.040), 'Per 10 g increase/day' (p-value=0.10), 'Per 2-fold increase/day' (p-value=0.24), 'Adherence to guidelines' (p-values for partial and non-adherence of 0.69 and 0.28, respectively.

Figure legends

- Figure 1. Flowchart of study participants.
- **Figure 2.** Odds ratios (ORs) and 95% confidence intervals (CIs) for presence of non-advanced adenoma and advanced lesions relative to controls for participants consuming *vs.* not consuming alcohol, as well as the different types of alcoholic beverages in the study overall (n=1,486) and by sex (660 women, 826 men).
- **Figure 3**. Associations of alcohol intake with the α -diversity indices Shannon and Inverse Simpson (a-c) and β -diversity based on the Bray-Curtis dissimilarity metric (d-g).
- Figure 4. Differential abundance analyses of bacterial species by total alcohol intake and alcoholic beverage types.
- Figure 5. Differential abundance analyses of pathways by total alcohol intake and alcoholic beverage types.
- Figure 6. Causal mediation analysis.








Differentially abundant bacteria


Level of alcohol intake
madRxiv preprint doi: https://doi.org/10.1101/2024.10.17.24315656; this version posted October 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

>0-10ig/naxje available under മാറ്റോ പ്രവിശ് 4.0 International പ്രവേദ്യ (A)




b

Consumption/non consumption



Differentially abundant pathways

medRxiv preprint dgi: https://doi.org/10.1101/2024.10.17.24315656; this **Level of Selection of**



b

Consumption/non consumption

